Advertisement
Canada markets close in 4 hours 40 minutes

  • S&P/TSX

    21,763.50
    -110.22 (-0.50%)
     

  • S&P 500

    5,005.91
    -65.72 (-1.30%)
     

  • DOW

    37,851.65
    -609.27 (-1.58%)
     

  • CAD/USD

    0.7298
    +0.0000 (+0.01%)
     

  • CRUDE OIL

    82.34
    -0.47 (-0.57%)
     

  • Bitcoin CAD

    86,955.50
    -2,205.84 (-2.47%)
     

  • CMC Crypto 200

    1,372.81
    -9.76 (-0.71%)
     

  • GOLD FUTURES

    2,347.20
    +8.80 (+0.38%)
     

  • RUSSELL 2000

    1,966.75
    -28.67 (-1.44%)
     

  • 10-Yr Bond

    4.7120
    +0.0600 (+1.29%)
     

  • NASDAQ

    15,437.89
    -274.86 (-1.75%)
     

  • VOLATILITY

    17.03
    +1.06 (+6.64%)
     

  • FTSE

    8,067.72
    +27.34 (+0.34%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Today's Research Reports on Acerus Pharmaceuticals, GeneNews, Resverlogix and Hamilton Thorne

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / December 5, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketedgereport.com and get exclusive access to our numerous research reports and market updates.

The Market Edge Initiates Coverage on:

Acerus Pharmaceuticals Corporation
https://marketedgereport.com/report/ASP.TO/

GeneNews Limited
https://marketedgereport.com/report/GEN.TO/

Resverlogix Corp.
https://marketedgereport.com/report/RVX.TO/

Hamilton Thorne Ltd.
https://marketedgereport.com/report/HTL.V/

ADVERTISEMENT

Acerus Pharmaceuticals' stock had no change Tuesday, to close the day at $0.13. The stock recorded a trading volume of 56,100 shares, which was below its three months average volume of 112,714 shares. In the last year, Acerus Pharmaceuticals' shares have traded in a range of 0.12 - 0.42. The share price has gained 8.33% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.20 is lower than its 200-day moving average of $0.25. Shares of Acerus Pharmaceuticals have fallen approximately 55.17 percent year-to-date.

Access The Market Edge's Acerus Pharmaceuticals Corporation Research Report:
https://marketedgereport.com/report/ASP.TO/

On Tuesday, shares of GeneNews recorded a trading volume of 30,000 shares, which was below the three months average volume of 141,712 shares. The stock ended the day 16.67% higher at $0.04. The share price has fallen 85.42% from its 52 week high with a 52 week trading range of 0.03 - 0.24. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.046 is lower than its 200-day moving average of $0.065. Shares of GeneNews have fallen approximately 84.78 percent year-to-date.

Access The Market Edge's GeneNews Limited Research Report:
https://marketedgereport.com/report/GEN.TO/

Resverlogix's stock moved 2.08% lower Tuesday, to close the day at $3.29. The stock recorded a trading volume of 40,915 shares, which was below its three months average volume of 73,557 shares. In the last year, Resverlogix's shares have traded in a range of 1.11 - 4.31. The share price has gained 196.4% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.23 is greater than its 200-day moving average of $2.82. Shares of Resverlogix have gained approximately 60.49 percent year-to-date.

Access The Market Edge's Resverlogix Corp. Research Report:
https://marketedgereport.com/report/RVX.TO/

On Tuesday, shares of Hamilton Thorne recorded a trading volume of 98,680 shares, which was above the three months average volume of 80,598 shares. The stock ended the day flat at $0.96. The share price has fallen 25% from its 52 week high with a 52 week trading range of 0.69 - 1.28. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.02 is above its 200-day moving average of $1.00. Shares of the company are trading at a Price to Earnings ratio of 25.26. Shares of Hamilton Thorne have gained approximately 28 percent year-to-date.

Access The Market Edge's Hamilton Thorne Ltd. Research Report:
https://marketedgereport.com/report/HTL.V/

Our Actionable Research on Acerus Pharmaceuticals Corporation (TSX:ASP.TO), GeneNews Limited (TSX:GEN.TO), Resverlogix Corp. (TSX:RVX.TO) and Hamilton Thorne Ltd. (TSXV:HTL.V) can be downloaded free of charge at The Market Edge.

The Market Edge

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketedgereport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: MarketEdgeReport